EULAR Recommendations for Physical Activity in Arthritis
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
Read ArticleEULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
Read Article
Links:
Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
Links:
A 2026 Physician Survey to assess artificial intelligence and its use in Medical Practice has been published and follows earlier surveys around adoption and use. This is the third in a series of longitudinal surveys (prior waves 2023, 2024), enabling meaningful trend analysis. AI adoption has
Read Article
The TOGETHER-PsA trial has demonstrated the efficacy and safety of ixekizumab (IXE) administered with tirzepatide (TZP) in adult active psoriatic arthritis (PsA) patients who were overweight or obese.
Dr. John Cush @RheumNow( View Tweet )
Do shoes make a difference in osteoarthritis (OA)? Common advice often suggests that stable supportive shoes can improve arthritis symptoms in the knee, but does this apply to hip osteoarthritis?
Read Article
Links:
With apologies to Shakespeare, names are important. In health care, they can have ethical significance. The American College of Physicians has published a new ethics/position policy paper proclaiming that the term ‘provider’ should not be used to describe physicians, and using the blanket term
Read Article
The American College of Rheumatology (ACR) today applauded the recent passage of the Congressional CY 26 funding package that includes several important provisions, including extending Medicare telehealth payment flexibilities, improving transparency in pharmacy benefit management (PBM)
Read Article
Lancet Rheumatology has published the ALTO results - long term outcomes of the APIPPRA trial, demonstrating that treatment with abatacept (ABA) in at risk patients can delay progression to rheumatoid arthritis (RA) for up to 4 years.
Read Article
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
Retraction of rheumatology studies is not uncommon; a recent analysis shows retractions have risen substantially.
Read Article
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.